Melanoma Trial Tests Individualized Neoantigen Therapy at Scale
The phase 3 INTerpath-001 trial randomized 1,137 patients with stage IIB to IV melanoma at 157 sites, testing an individualized neoantigen therapy with a 6- to 8-week tumor-to-injection pathway.